Literature DB >> 3052006

The role of exercise testing in evaluation of arrhythmias.

P J Podrid1, F J Venditti, P A Levine, M D Klein.   

Abstract

Exercise testing has been widely applied for the evaluation of patients with coronary artery disease. The principles underlying its use for this indication make it a useful adjunctive technique, when combined with ambulatory monitoring, to diagnose arrhythmias and monitor antiarrhythmic drug therapy. During exercise, there is a withdrawal of vagal tone and a marked increase in circulating catecholamines and sympathetic inputs to the heart. These changes may directly cause arrhythmias (e.g., catecholamines can enhance automaticity and delayed afterpotentials and can shorten myocardial conduction time and refractory periods). However, they also augment myocardial oxygen demands by increasing myocardial inotropy, heart rate and blood pressure. Such changes may cause ischemia in patients with heart disease, which is a powerful stimulus for arrhythmia, or lead to dysfunction in left ventricular contraction and increased myocardial wall stress, factors that also may precipitate arrhythmia. In approximately 10% of patients with a history of serious arrhythmia, exercise represents the only means for exposing arrhythmia. Importantly, this technique is useful for evaluating the effect of antiarrhythmic drugs. These agents work by reducing membrane automaticity, slowing impulse conduction through the myocardium and prolonging membrane refractoriness. In contrast, catecholamines, which are secreted in response to exercise, have the opposite effect. Thus, exercise may negate the important effects of the antiarrhythmic drugs. Additionally, exercise testing may expose potentially serious toxic drug reactions that may not be obvious at rest. These include conduction abnormalities, negative inotropic effects, congestive heart failure and aggravation of arrhythmia. Although the presence and frequency of arrhythmia with exercise is highly variable in patients with benign arrhythmia, results are more consistent in patients with a history of serious arrhythmia. If arrhythmia is reproducibly provoked with exercise, this technique can be used to judge drug effect. Thus, exercise testing is an important, reliable and helpful technique for exposing arrhythmia, evaluating drug efficacy and identifying potentially serious toxic drug effects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3052006     DOI: 10.1016/0002-9149(88)90337-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Adrenergic nervous system influences on the induction of ventricular tachycardia.

Authors:  Oscar A Pellizzón; Juan S Beloscar; Enrique Mariani
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-10       Impact factor: 1.468

Review 2.  Diagnosis and management of ventricular tachycardia.

Authors:  M Dancy
Journal:  Postgrad Med J       Date:  1992-06       Impact factor: 2.401

3.  Cardiac arrhythmias triggered by sudden and dynamic efforts.

Authors:  Emanuel C Furtado; Claudio Gil S Araújo
Journal:  Ann Noninvasive Electrocardiol       Date:  2010-04       Impact factor: 1.468

4.  ECG changes during ISWTs in adult patients commencing CR: a retrospective case note review.

Authors:  Alexandra Palma; Charlotte Pereira; Heather Probert; Harriet Shannon
Journal:  Br J Cardiol       Date:  2021-03-09

5.  Diagnostic usefulness of graded exercise testing in pediatric supraventricular tachycardia.

Authors:  David E Draper; Niels G Giddins; Joy McCort; Gil J Gross
Journal:  Can J Cardiol       Date:  2009-07       Impact factor: 5.223

6.  Stretchable PPG sensor with light polarization for physical activity-permissible monitoring.

Authors:  Gae Hwang Lee; Hyunbum Kang; Jong Won Chung; Yeongjun Lee; Hyunjun Yoo; Sujin Jeong; Hyeon Cho; Joo-Young Kim; Sung-Gyu Kang; Ji Young Jung; Suk Gyu Hahm; Jeahyuck Lee; In-Jo Jeong; Minho Park; Gunkuk Park; In Ho Yun; Justin Younghyun Kim; Yongtaek Hong; Youngjun Yun; Sung-Han Kim; Byoung Ki Choi
Journal:  Sci Adv       Date:  2022-04-13       Impact factor: 14.136

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.